FI3802807T3 - Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja menetelmiä niiden käyttämiseksi - Google Patents
Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja menetelmiä niiden käyttämiseksi Download PDFInfo
- Publication number
- FI3802807T3 FI3802807T3 FIEP19732821.4T FI19732821T FI3802807T3 FI 3802807 T3 FI3802807 T3 FI 3802807T3 FI 19732821 T FI19732821 T FI 19732821T FI 3802807 T3 FI3802807 T3 FI 3802807T3
- Authority
- FI
- Finland
- Prior art keywords
- dna sequence
- target dna
- polypeptide
- sequence
- rgn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/301—Endonuclease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862680845P | 2018-06-05 | 2018-06-05 | |
| US201862680853P | 2018-06-05 | 2018-06-05 | |
| US201862680862P | 2018-06-05 | 2018-06-05 | |
| US201862680846P | 2018-06-05 | 2018-06-05 | |
| US201862680863P | 2018-06-05 | 2018-06-05 | |
| US201862680859P | 2018-06-05 | 2018-06-05 | |
| US201862686901P | 2018-06-19 | 2018-06-19 | |
| US201962805041P | 2019-02-13 | 2019-02-13 | |
| US201962805045P | 2019-02-13 | 2019-02-13 | |
| PCT/US2019/035373 WO2019236566A1 (en) | 2018-06-05 | 2019-06-04 | Rna-guided nucleases and active fragments and variants thereof and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3802807T3 true FI3802807T3 (fi) | 2025-02-19 |
Family
ID=67002401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19732821.4T FI3802807T3 (fi) | 2018-06-05 | 2019-06-04 | Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja menetelmiä niiden käyttämiseksi |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US11162114B2 (https=) |
| EP (2) | EP3802807B1 (https=) |
| JP (2) | JP7708660B2 (https=) |
| KR (1) | KR20210089629A (https=) |
| CN (1) | CN113015797A (https=) |
| AU (2) | AU2019282149B2 (https=) |
| BR (1) | BR112020024863A2 (https=) |
| CA (1) | CA3102840A1 (https=) |
| DK (1) | DK3802807T3 (https=) |
| ES (1) | ES3011849T3 (https=) |
| FI (1) | FI3802807T3 (https=) |
| IL (2) | IL279222B2 (https=) |
| MX (1) | MX2020013124A (https=) |
| PL (1) | PL3802807T3 (https=) |
| PT (1) | PT3802807T (https=) |
| SG (1) | SG11202011975WA (https=) |
| TW (1) | TW202532650A (https=) |
| WO (1) | WO2019236566A1 (https=) |
| ZA (1) | ZA202008045B (https=) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| EP3204496A1 (en) | 2014-10-10 | 2017-08-16 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| JP2020510038A (ja) | 2017-03-09 | 2020-04-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | がんワクチン |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| JP7657726B2 (ja) | 2019-03-19 | 2025-04-07 | ザ ブロード インスティテュート，インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| KR20220062289A (ko) | 2019-08-12 | 2022-05-16 | 라이프에디트 테라퓨틱스, 인크. | Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| KR102776469B1 (ko) * | 2019-12-10 | 2025-03-05 | 인스크립타 인코포레이티드 | 신규 mad 뉴클레아제 |
| US20230203463A1 (en) * | 2019-12-30 | 2023-06-29 | LifeEDIT Therapeutics, Inc. | Rna-guided nucleases and active fragments and variants thereof and methods of use |
| TW202208626A (zh) * | 2020-04-24 | 2022-03-01 | 美商生命編輯公司 | Rna引導核酸酶及其活性片段與變體，以及使用方法 |
| WO2021222318A1 (en) * | 2020-04-28 | 2021-11-04 | The Broad Institute, Inc. | Targeted base editing of the ush2a gene |
| DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
| GB202007943D0 (en) | 2020-05-27 | 2020-07-08 | Snipr Biome Aps | Products & methods |
| CA3174356A1 (en) | 2020-07-01 | 2022-01-06 | Santosh NARAYAN | Compositions and methods for cellular reprogramming using circular rna |
| JP2023534693A (ja) | 2020-07-15 | 2023-08-10 | ライフエディット セラピューティクス，インコーポレイティド | ウラシル安定化タンパク質並びにその活性断片及びバリアント並びに使用方法 |
| WO2022027035A1 (en) * | 2020-07-27 | 2022-02-03 | The Children's Hospital Of Philadelphia | In utero and postnatal gene editing and therapy for treatment of monogenic diseases, including mucopolysaccharidosis type 1h and other disorders |
| TWI910226B (zh) | 2020-09-11 | 2026-01-01 | 美商生命編輯治療學公司 | Ｄｎａ修飾酶及活性片段，及其變異體與使用方法 |
| CA3202977A1 (en) | 2020-12-22 | 2022-06-30 | Chroma Medicine, Inc. | Compositions and methods for epigenetic editing |
| CN117295817A (zh) | 2021-03-22 | 2023-12-26 | 生命编辑制药股份有限公司 | Dna修饰酶及其活性片段和变体以及使用方法 |
| AU2022290278A1 (en) | 2021-06-11 | 2024-01-04 | LifeEDIT Therapeutics, Inc. | Rna polymerase iii promoters and methods of use |
| CA3244778A1 (en) * | 2022-02-23 | 2023-08-31 | Metagenomi Therapeutics, Inc. | SYSTEMS AND METHODS FOR TRANSPOSING CARGO NUCLEOTID SEQUENCES |
| CN117925585A (zh) * | 2022-04-07 | 2024-04-26 | 尧唐(上海)生物科技有限公司 | 腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途 |
| EP4519293A1 (en) | 2022-05-01 | 2025-03-12 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of pcsk9 expression |
| EP4544058A1 (en) | 2022-06-23 | 2025-04-30 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of ciita expression |
| WO2023250148A1 (en) | 2022-06-23 | 2023-12-28 | Chroma Medicine, Inc. | Compositions and methods for epigenetic editing |
| WO2023250509A1 (en) | 2022-06-23 | 2023-12-28 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of b2m expression |
| US20250387514A1 (en) | 2022-06-23 | 2025-12-25 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of trac expression |
| TW202424186A (zh) | 2022-08-25 | 2024-06-16 | 美商生命編輯治療學公司 | Rna引導核酸酶中介基因編輯用之具鎖核酸引導 rna之化學修飾 |
| CN115820636B (zh) * | 2022-09-02 | 2024-06-11 | 华南农业大学 | 靶向TP53基因的sgRNA及其应用 |
| KR20250110209A (ko) | 2022-09-23 | 2025-07-18 | 엔크로마 바이오, 인크. | Hbv 유전자 발현의 에피제네틱 조절을 위한 조성물 및 방법 |
| WO2024081879A1 (en) | 2022-10-14 | 2024-04-18 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of cd247 expression |
| EP4612284A2 (en) | 2022-11-04 | 2025-09-10 | Life Edit Therapeutics, Inc. | Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use |
| WO2024178397A2 (en) | 2023-02-24 | 2024-08-29 | Elevatebio Technologies, Inc. | Modified immune effector cells and methods of use |
| IL324634A (en) | 2023-05-15 | 2026-01-01 | Nchroma Bio Inc | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2024238700A1 (en) | 2023-05-15 | 2024-11-21 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| TW202546224A (zh) | 2024-02-12 | 2025-12-01 | 美商生命編輯治療學公司 | 新穎的ｒｎａ引導之核酸酶及用於聚合酶編輯之蛋白質 |
| WO2026003754A1 (en) | 2024-06-25 | 2026-01-02 | Life Edit Therapeutics, Inc. | Novel reverse transcriptases and uses thereof |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US457A (en) | 1837-11-11 | Caleb slade | ||
| US699A (en) | 1838-04-21 | stone | ||
| US9840A (en) | 1853-07-12 | Improvement in tanning | ||
| US10167A (en) | 1853-10-25 | Soda-jountaiet | ||
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5380831A (en) | 1986-04-04 | 1995-01-10 | Mycogen Plant Science, Inc. | Synthetic insecticidal crystal protein gene |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5569597A (en) | 1985-05-13 | 1996-10-29 | Ciba Geigy Corp. | Methods of inserting viral DNA into plant material |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4853331A (en) | 1985-08-16 | 1989-08-01 | Mycogen Corporation | Cloning and expression of Bacillus thuringiensis toxin gene toxic to beetles of the order Coleoptera |
| US5268463A (en) | 1986-11-11 | 1993-12-07 | Jefferson Richard A | Plant promoter α-glucuronidase gene construct |
| US5608142A (en) | 1986-12-03 | 1997-03-04 | Agracetus, Inc. | Insecticidal cotton plants |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5039523A (en) | 1988-10-27 | 1991-08-13 | Mycogen Corporation | Novel Bacillus thuringiensis isolate denoted B.t. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin |
| EP0463056A1 (en) | 1989-03-17 | 1992-01-02 | E.I. Du Pont De Nemours And Company | External regulation of gene expression |
| EP0452269B1 (en) | 1990-04-12 | 2002-10-09 | Syngenta Participations AG | Tissue-preferential promoters |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5498830A (en) | 1990-06-18 | 1996-03-12 | Monsanto Company | Decreased oil content in plant seeds |
| CA2051562C (en) | 1990-10-12 | 2003-12-02 | Jewel M. Payne | Bacillus thuringiensis isolates active against dipteran pests |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5399680A (en) | 1991-05-22 | 1995-03-21 | The Salk Institute For Biological Studies | Rice chitinase promoter |
| CA2116449C (en) | 1991-08-27 | 2005-04-05 | Vaughan Alan Hilder | Proteins with insecticidal properties against homopteran insects and their use in plant protection |
| TW261517B (https=) | 1991-11-29 | 1995-11-01 | Mitsubishi Shozi Kk | |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5789156A (en) | 1993-06-14 | 1998-08-04 | Basf Ag | Tetracycline-regulated transcriptional inhibitors |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5608144A (en) | 1994-08-12 | 1997-03-04 | Dna Plant Technology Corp. | Plant group 2 promoters and uses thereof |
| US5659026A (en) | 1995-03-24 | 1997-08-19 | Pioneer Hi-Bred International | ALS3 promoter |
| US6072050A (en) | 1996-06-11 | 2000-06-06 | Pioneer Hi-Bred International, Inc. | Synthetic promoters |
| CA2315546C (en) | 1998-02-26 | 2008-04-29 | Pioneer Hi-Bred International, Inc. | Constitutive maize promoters |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| CZ20013894A3 (cs) | 1999-05-04 | 2002-04-17 | Monsanto Technology Llc | Polypeptidové kompozice toxické pro hmyz z řádu Coleoptera a transgenní rostliny rezistentní proti hmyzu |
| AU7491600A (en) | 1999-09-15 | 2001-04-17 | Monsanto Technology Llc | Lepidopteran-active bacillus thuringiensis delta-endotoxin compositions and methods of use |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| US20050183161A1 (en) | 2003-10-14 | 2005-08-18 | Athenix Corporation | AXMI-010, a delta-endotoxin gene and methods for its use |
| US7629504B2 (en) | 2003-12-22 | 2009-12-08 | Pioneer Hi-Bred International, Inc. | Bacillus thuringiensis cry9 nucleic acids |
| NZ573398A (en) | 2006-06-14 | 2011-11-25 | Athenix Corp | Axmi-031, axmi-039, axmi-040 and axmi-049, a family of delta-endotoxin genes and methods for their use |
| EP2334794B8 (en) | 2008-09-15 | 2017-04-19 | The Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
| MX346215B (es) | 2009-07-02 | 2017-03-10 | Athenix Corp | Gen plaguicida axmi-205 y metodos para su uso. |
| WO2011084324A2 (en) | 2009-12-21 | 2011-07-14 | Pioneer Hi-Bred International, Inc. | Novel bacillus thuringiensis gene with lepidopteran activity |
| WO2012024200A2 (en) | 2010-08-19 | 2012-02-23 | Pioneer Hi-Bred International, Inc. | Novel bacillus thuringiensis gene with lepidopteran activity |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| EP3241902B1 (en) * | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| DK3444342T3 (da) | 2012-07-11 | 2020-08-24 | Sangamo Therapeutics Inc | Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme |
| EP3760719A1 (en) * | 2013-11-18 | 2021-01-06 | CRISPR Therapeutics AG | Crispr-cas system materials and methods |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP3633032A3 (en) | 2014-08-28 | 2020-07-29 | North Carolina State University | Novel cas9 proteins and guiding features for dna targeting and genome editing |
| CN107849546A (zh) * | 2015-05-15 | 2018-03-27 | 先锋国际良种公司 | 对cas内切核酸酶系统、pam序列和指导rna元件的快速表征 |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP4400597A3 (en) * | 2015-10-09 | 2024-10-16 | Monsanto Technology LLC | Novel rna-guided nucleases and uses thereof |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| EP3699281A1 (en) * | 2016-03-11 | 2020-08-26 | Pioneer Hi-Bred International, Inc. | Novel cas9 systems and methods of use |
| CA3010628A1 (en) * | 2016-03-11 | 2017-09-14 | Pioneer Hi-Bred International, Inc. | Novel cas9 systems and methods of use |
| CA3018430A1 (en) * | 2016-06-20 | 2017-12-28 | Pioneer Hi-Bred International, Inc. | Novel cas systems and methods of use |
| KR102547316B1 (ko) | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| US12431216B2 (en) * | 2016-08-17 | 2025-09-30 | Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| EP3526320A1 (en) * | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| WO2018089664A1 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Variant rna-guided polypeptides and methods of use |
| ES2970169T3 (es) * | 2018-12-27 | 2024-05-27 | Lifeedit Therapeutics Inc | Polipéptidos útiles para edición génica y métodos de uso |
-
2019
- 2019-06-04 BR BR112020024863A patent/BR112020024863A2/pt unknown
- 2019-06-04 AU AU2019282149A patent/AU2019282149B2/en active Active
- 2019-06-04 CN CN201980044318.0A patent/CN113015797A/zh active Pending
- 2019-06-04 SG SG11202011975WA patent/SG11202011975WA/en unknown
- 2019-06-04 EP EP19732821.4A patent/EP3802807B1/en active Active
- 2019-06-04 ES ES19732821T patent/ES3011849T3/es active Active
- 2019-06-04 CA CA3102840A patent/CA3102840A1/en active Pending
- 2019-06-04 MX MX2020013124A patent/MX2020013124A/es unknown
- 2019-06-04 JP JP2021518031A patent/JP7708660B2/ja active Active
- 2019-06-04 FI FIEP19732821.4T patent/FI3802807T3/fi active
- 2019-06-04 KR KR1020217000176A patent/KR20210089629A/ko active Pending
- 2019-06-04 IL IL279222A patent/IL279222B2/en unknown
- 2019-06-04 EP EP24213965.7A patent/EP4512900A3/en active Pending
- 2019-06-04 PL PL19732821.4T patent/PL3802807T3/pl unknown
- 2019-06-04 PT PT197328214T patent/PT3802807T/pt unknown
- 2019-06-04 DK DK19732821.4T patent/DK3802807T3/da active
- 2019-06-04 WO PCT/US2019/035373 patent/WO2019236566A1/en not_active Ceased
- 2019-06-04 IL IL321042A patent/IL321042A/en unknown
- 2019-06-05 TW TW113138899A patent/TW202532650A/zh unknown
- 2019-06-05 US US16/432,321 patent/US11162114B2/en active Active
-
2020
- 2020-12-22 ZA ZA2020/08045A patent/ZA202008045B/en unknown
-
2021
- 2021-09-17 US US17/478,374 patent/US11926843B2/en active Active
-
2024
- 2024-02-02 US US18/431,662 patent/US12338455B2/en active Active
-
2025
- 2025-05-22 US US19/216,399 patent/US20250283117A1/en active Pending
- 2025-07-03 JP JP2025113206A patent/JP2025133875A/ja active Pending
- 2025-11-20 AU AU2025271070A patent/AU2025271070A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3802807T3 (fi) | Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja menetelmiä niiden käyttämiseksi | |
| FI4118198T3 (fi) | Rna-ohjattuja nukleaaseja ja niiden aktiivisia fragmentteja ja variantteja ja käyttömenetelmiä | |
| JP7153992B2 (ja) | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 | |
| JP7038079B2 (ja) | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 | |
| JP2021118726A5 (https=) | ||
| EP3178935B1 (en) | Genome editing using campylobacter jejuni crispr/cas system-derived rgen | |
| US10612043B2 (en) | Methods of in vivo engineering of large sequences using multiple CRISPR/cas selections of recombineering events | |
| US20180016601A1 (en) | Methods for Modulating Genome Editing | |
| JP2021530988A5 (https=) | ||
| CN109136248B (zh) | 多靶点编辑载体及其构建方法和应用 | |
| JPWO2019236566A5 (https=) | ||
| WO2019232069A1 (en) | Cell therapy | |
| JPWO2021030344A5 (https=) | ||
| WO2018117746A1 (ko) | 동물 배아의 염기 교정용 조성물 및 염기 교정 방법 | |
| JP7684298B2 (ja) | Ｒｎａ分子を合成する方法 | |
| CN104560995B (zh) | 一对特异识别猪H11位点的sgRNA及其编码DNA和应用 | |
| WO2021058984A1 (en) | A nucleic acid delivery vector comprising a circular single stranded polynucleotide | |
| WO2023206872A1 (zh) | 一种工程优化的核酸酶、向导rna、编辑系统和应用 | |
| CN104531685A (zh) | 特异识别猪H11位点的sgRNA及其编码DNA和应用 | |
| US20210155927A1 (en) | Methods for treating sickle cell disease | |
| JPWO2020223514A5 (https=) | ||
| EP4602156A2 (en) | Compositions, methods, and systems for dna modification | |
| EP4230737A1 (en) | Novel enhanced base editing or revising fusion protein and use thereof | |
| US20230159957A1 (en) | Compositions and methods for modifying a target nucleic acid | |
| CN112501171B (zh) | 两条特异性靶向猪Pax7基因的sgRNA导向序列及应用 |